These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2759349)

  • 1. Status of WHO concerning continuous cell lines as substrates for the production of biologicals.
    Grachev V; Magrath D
    Dev Biol Stand; 1989; 70():215-9. PubMed ID: 2759349
    [No Abstract]   [Full Text] [Related]  

  • 2. Should continuous cell lines be used as substrates for biological products?
    Petricciani JC
    Dev Biol Stand; 1987; 66():3-12. PubMed ID: 3582759
    [No Abstract]   [Full Text] [Related]  

  • 3. Viral safety of biological products in WHO policy.
    Grachev VP
    Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50).
    Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.
    Knezevic I; Stacey G; Petricciani J; Sheets R;
    Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
    [No Abstract]   [Full Text] [Related]  

  • 7. Current experience with biological products produced in various continuous cell lines. Summary and conclusions.
    Papermaster BW
    Dev Biol Stand; 1989; 70():227-9. PubMed ID: 2759350
    [No Abstract]   [Full Text] [Related]  

  • 8. World Health Organization attitude concerning the use of continuous cell lines as substrates for production of human virus vaccines.
    Grachev VP
    Adv Biotechnol Processes; 1990; 14():37-67. PubMed ID: 2222837
    [No Abstract]   [Full Text] [Related]  

  • 9. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals: application to influenza vaccine production.
    Griffiths E
    Dev Biol Stand; 1999; 98():153-7; discussion 167. PubMed ID: 10494968
    [No Abstract]   [Full Text] [Related]  

  • 10. Acceptability of cell substrates for production of biologicals. Report of a WHO Study Group on Biologicals.
    World Health Organ Tech Rep Ser; 1987; 747():1-29. PubMed ID: 3107222
    [No Abstract]   [Full Text] [Related]  

  • 11. WHO Expert Committee on Biological Standardization. Forty-sixth Report.
    World Health Organ Tech Rep Ser; 1998; 872():i-vii, 1-90. PubMed ID: 9615608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHO Expert Committee On Biological Standardization.
    World Health Organ Tech Rep Ser; 1998; 878():i-vi, 1-101. PubMed ID: 9731464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of biologicals produced in continuous cell lines.
    Hoffman T; Fratantoni J; Murano G
    Dev Biol Stand; 1989; 70():211-4. PubMed ID: 2668073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. History of cell substrates used for human biologicals.
    Hayflick L
    Dev Biol Stand; 1989; 70():11-26. PubMed ID: 2668070
    [No Abstract]   [Full Text] [Related]  

  • 16. Current USDA procedures for licensing biotechnology-derived veterinary biologicals.
    Gay CG
    Dev Biol Stand; 1992; 79():65-74. PubMed ID: 1286767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WHO Expert Committee on biological standardization.
    World Health Organ Tech Rep Ser; 2007; (941):1-340, back cover. PubMed ID: 18314862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologicals and vaccines: regulatory perspectives.
    Petricciani JC
    Dev Biol Stand; 1986; 63():15-9. PubMed ID: 3743903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHO Expert Committee on Biological Standardization.
    Horowitz B; Minor P; Morgenthaler JJ; Burnouf T; McIntosh R; Padilla A; Thorpe R; van Aken WG;
    World Health Organ Tech Rep Ser; 2004; 924():1-232, backcover. PubMed ID: 15693660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.